FDA Registers 9-Strain HPV Vaccine and Botulinum Antitoxin

MGR Online•Politics•1d ago

Reader Briefing

The Thai FDA has registered a 9-strain HPV vaccine and a Botulinum Antitoxin to enhance national vaccine security and position Thailand as an ASEAN vaccine hub.

•The FDA registered the 9-strain HPV vaccine on July 24, 2026, and the Botulinum Antitoxin on July 6, 2026.
•The National Vaccine Institute collaborated with INNOVAX for the transfer of HPV vaccine production technology from 2024 to 2026.
•The Botulinum Antitoxin (TRCS BOTULINUM ANTITOXIN) was developed with the Queen Saovabha Memorial Institute, marking the first Bivalent (AB) production in Thailand and ASEAN.
•Prime Minister Anutin Charnvirakul presided over a public relations activity on August 25, 2026, at Government House.

Overview

•Prime Minister Anutin Charnvirakul attended a public relations event on August 25, 2026, to showcase Thailand's vaccine production potential.
•The Food and Drug Administration (FDA) registered the 9-strain HPV vaccine on July 24, 2026.
•The Food and Drug Administration (FDA) registered the Botulinum Antitoxin on July 6, 2026.
•The National Vaccine Institute collaborated with INNOVAX for technology transfer between 2024 and 2026.
•INNOVAX has supplied 2-strain HPV vaccines since 2023 at a rate of 800,000 doses per year, covering approximately 1.2 million eligible children over 3 academic years.
•The production of the Bivalent (AB) Botulinum Antitoxin by the Queen Saovabha Memorial Institute reduces import reliance and prepares Thailand to be a regional reserve center.
•The National Vaccine Institute has served as a Program Management Unit (PMU) under the Science Research and Innovation Fund since 2022.
•The National Vaccine Institute promotes vaccine research and technology transfer to ensure sufficient vaccine supply for the population during normal and emergency situations.

Full article content is available on the original source.

Read on MGR Online (Thai Version)View in Google Translate

Source: MGR Online (Original)

View Original Article

Key Entities

Organization

Food and Drug Administration(สำนักงานคณะกรรมการอาหารและยา)ℹ️

The agency that registered the 9-strain HPV vaccine and the Botulinum Antitoxin.

National Vaccine Institute(สถาบันวัคซีนแห่งชาติ)

The organization driving strategic cooperation for vaccine production and serving as a Program Management Unit under the Science Research and Innovation Fund.

Ministry of Public Health(กระทรวงสาธารณสุข)

The ministry overseeing the National Vaccine Institute.

INNOVAX

The company that collaborated with the National Vaccine Institute for the transfer of HPV vaccine production technology.

Queen Saovabha Memorial Institute, Thai Red Cross Society(สถานเสาวภา สภากาชาดไทย)

The organization that collaborated to develop the Bivalent (AB) Botulinum Antitoxin.

Science Research and Innovation Fund(กองทุนส่งเสริมวิทยาศาสตร์ วิจัยและนวัตกรรม)

The fund under which the National Vaccine Institute operates as a Program Management Unit.

Ministry of Interior(กระทรวงมหาดไทย)ℹ️

The ministry where Anutin Charnvirakul serves as Minister.

Person

Ratchada Thanadirek(รัชดา ธนาดิเรก)

The spokesperson for the Office of the Prime Minister.

Anutin Charnvirakul(อนุทิน ชาญวีรกูล)ℹ️

The Prime Minister and Minister of Interior.

Place

Government House(ทำเนียบรัฐบาล)ℹ️

The location where the public relations activity was held on August 25, 2026.